300318.SZ
300318.SZ
CNE000001QR4
BOHUI INNOVATION
Loading chart...

Company Profile

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of in-vitro diagnostic products in China and internationally. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; human serum albumin; human prothrombin complex and human coagulation factor VIII; and vaccine for rabies. It also provides molecular diagnostics platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others. In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.

Related stocks

688639.SS
688639.SS • China
ANHUI HUAHENG BIOTECHNOLOGY CO
19.34 CNY
723.81M USD 1Y -44.2%
2617.HK
2617.HK • China
TRANSTHERA-B
10.43 HKD
541.23M USD 1Y -92.1%
1167.HK
1167.HK • China
JACOBIO-B
5.57 HKD
555.2M USD 1Y -36.4%
9887.HK
9887.HK • China
LEADS BIOLABS-B
45.56 HKD
1.15B USD 1Y -37.5%
2616.HK
2616.HK • China
CSTONE PHARMA-B
5.09 HKD
1.03B USD 1Y -33.8%
2171.HK
2171.HK • China
CARSGEN-B
11.63 HKD
844.52M USD 1Y -39.7%
688526.SS
688526.SS • China
WUHAN KEQIAN BIOLOGY CO LTD
12.41 CNY
865.58M USD 1Y -29.4%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
45.2% p.a.
Max Drawdown (5Y)
-67.7%
Sharpe Ratio (5Y)
-0.23
Beta Factor
0.08
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -82.3% in the extended horizon.
ende